OVERLAND PARK, Kan.; November 8, 2022 (ACCESSWIRE) – Dr. Vince Clinical Research (DVCR), a world-class early phase contract research organization (CRO) specializing in the conduct of Phase I clinical trials, today announced that it has administered the first dose in...
Study Conducted by Dr. Vince Clinical Research KANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and...
OVERLAND PARK, Kan.–(BUSINESS WIRE)–Dr. Vince Clinical Research (DVCR), today announced the launch of its new, world-class clinical pharmacology unit and headquarters in Overland Park, Kansas. The custom-built, green-inspired research complex was...
PRINCETON, N.J. & OVERLAND PARK, Kan.–(BUSINESS WIRE)–WCG, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the expansion of its Phase I review services, providing...
OVERLAND PARK, Kan.; July 26, 2022 (Business Wire) – Dr. Vince Clinical Research (DVCR), a world-class contract research organization (CRO) specializing in early phase clinical trials, today announced the addition of two key leadership roles to its Phase I...
OVERLAND PARK, KS, December 7, 2021 – Dr. Vince Clinical Research (DVCR) added depth to its medical team with the addition of industry veteran Steven Hull, M.D., FCCP, FAASM, as a Principal Investigator for the new clinical research organization. Dr. Hull joins DVCR...
Recent Comments